Summer 2026
Develops therapies for serious genetic diseases
$20 - $35/hr
No H1B Sponsorship
Boston, MA, USA
Hybrid
Hybrid role with 3 days on-site per week in Boston.
| , |
Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
People at Vertex Pharmaceuticals who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
MBAE honors rep. Alice Peisch and Vertex Pharmaceuticals for advancing educational opportunity. June 8, 2026 MBAE honored Representative Alice Hanlon Peisch and Vertex Pharmaceuticals at its annual Leadership in Education Awards luncheon for their outstanding contributions to expanding educational opportunity and advancing student success across Massachusetts. Representative Peisch received the MBAE Paul Reville Leadership in Education Award in recognition of more than two decades of public service and unwavering commitment to educational equity and opportunity. Since joining the Massachusetts House of Representatives in 2003, Peisch has been a leading advocate for educational excellence, equity, and accountability. As chair of the Joint Committee on Education from 2011 to 2023, she helped advance major reforms in school finance, special education, educator preparation, and literacy. She co-chaired the 2014 Foundation Budget Review Commission, whose recommendations helped shape the landmark Student Opportunity Act, and served on the National Assessment Governing Board, including as vice chair through 2024. The award was presented to Representative Peisch by Massachusetts Secretary of Education Stephen Zrike who along with Commissioner Pedro Martinez shared remarks during the event. The MBAE Jack Rennie Award for Business Impact in Education was presented to Vertex Pharmaceuticals and the Vertex Foundation for their commitment to advancing education, innovation, and community well-being. A leading corporate citizen in Massachusetts, Vertex partners with schools, nonprofits, and community organizations to expand access to STEAM (Science, Technology, Engineering, Arts, and Math) education, particularly for students from historically underrepresented and under-resourced communities. Through mentorship, hands-on learning experiences, and exposure to STEM careers, Vertex helps students envision pathways into science and innovation. MBAE's awards are named in honor of its co-founders, Paul Reville and Jack Rennie, who together led a five-year push for sweeping reform in the state's K-12 education system, resulting in the Massachusetts Education Reform Act of 1993. Reville later served as Massachusetts Secretary of Education. MBAE's annual awards luncheon celebrates the business community's commitment to excellence in public education.
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?
Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter, valued at approximately $2.19 million, according to a recent 13F filing with the Securities and Exchange Commission. The investment reflects confidence in the Boston-based biotechnology company, which specialises in developing treatments for serious diseases, particularly cystic fibrosis. Vertex's portfolio of CFTR modulators has transformed standards of care for many CF patients. Vertex's share price has risen over 20% in the past year as the company continues expanding its cystic fibrosis treatments and exploring new therapeutic areas. The investment signals institutional interest in Vertex's growth potential and drug pipeline.
Halozyme and Vertex sign deal for Hypercon technology. Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments. Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: "This collaboration with Vertex underscores the versatility and potential of its Hypercon technology to enable small volume, patient-delivered next generation biologics. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." Halozyme's Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio's polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter's Enhanze drug delivery technology. Give your business an edge with its leading industry insights.
Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026